The North America Endometriosis Market would witness market growth of 11.0% CAGR during the forecast period (2022-2028).
Endometriosis does not have a known aetiology. There have been various hypotheses put forth. The disorder typically runs in families. Additionally, it has a greater impact on some ethnic groups than others. The fallopian tubes allow some of the uterine lining to rise. Instead of exiting the body as a period, it embeds itself in the pelvic organs. The body's built-in defence against disease and infection has a problem.
Endometrium cells migrate across the body through the lymphatic or blood systems. The immune system is made up of a number of tubes and glands. These hypotheses do not fully elucidate the causes of endometriosis. The illness is probably brought on by a number of different factors working together.
Women frequently experience the health issue of endometriosis. More than 6.5 million women in the US, or at least 11% of all women, are thought to have endometriosis. Endometriosis develops when tissue that resembles the uterine lining (womb lining) grows outside of the uterus. More than 11% of American women between the ages of 15 and 44 may be affected. It may make it more difficult to become pregnant and is particularly prevalent in women in their 30s and 40s. The symptoms can be controlled with a variety of treatments, which can also increase the chances of getting pregnant. The high endometriosis prevalence in North America is anticipated to increase the demand for endometriosis therapy.
The US market dominated the North America Endometriosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $615.8 million by 2028. The Canada market is poised to grow at a CAGR of 13.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 12.5% during (2022 - 2028).
Based on Type, the market is segmented into Superficial Peritoneal Lesion, Endometriomas, and Others. Based on Treatment, the market is segmented into Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
Endometriosis does not have a known aetiology. There have been various hypotheses put forth. The disorder typically runs in families. Additionally, it has a greater impact on some ethnic groups than others. The fallopian tubes allow some of the uterine lining to rise. Instead of exiting the body as a period, it embeds itself in the pelvic organs. The body's built-in defence against disease and infection has a problem.
Endometrium cells migrate across the body through the lymphatic or blood systems. The immune system is made up of a number of tubes and glands. These hypotheses do not fully elucidate the causes of endometriosis. The illness is probably brought on by a number of different factors working together.
Women frequently experience the health issue of endometriosis. More than 6.5 million women in the US, or at least 11% of all women, are thought to have endometriosis. Endometriosis develops when tissue that resembles the uterine lining (womb lining) grows outside of the uterus. More than 11% of American women between the ages of 15 and 44 may be affected. It may make it more difficult to become pregnant and is particularly prevalent in women in their 30s and 40s. The symptoms can be controlled with a variety of treatments, which can also increase the chances of getting pregnant. The high endometriosis prevalence in North America is anticipated to increase the demand for endometriosis therapy.
The US market dominated the North America Endometriosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $615.8 million by 2028. The Canada market is poised to grow at a CAGR of 13.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 12.5% during (2022 - 2028).
Based on Type, the market is segmented into Superficial Peritoneal Lesion, Endometriomas, and Others. Based on Treatment, the market is segmented into Oral Contraceptives, Gonadotropin-releasing hormone (GnRH) medicines, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Superficial Peritoneal Lesion
- Endometriomas
- Others
By Treatment
- Oral Contraceptives
- Gonadotropin-releasing hormone (GnRH) medicines
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Teva Pharmaceuticals Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Sanofi S.A
- AbbVie, Inc
- AstraZeneca PLC
- Pfizer, Inc
- Merck & Co., Inc
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Endometriosis Market, by Type
1.4.2 North America Endometriosis Market, by Treatment
1.4.3 North America Endometriosis Market, by Distribution Channel
1.4.4 North America Endometriosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Endometriosis Market by Type
3.1 North America Superficial Peritoneal Lesion Market by Country
3.2 North America Endometriomas Market by Country
3.3 North America Others Market by Country
Chapter 4. North America Endometriosis Market by Treatment
4.1 North America Oral Contraceptives Market by Country
4.2 North America Gonadotropin-releasing hormone (GnRH) medicines Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Endometriosis Market by Distribution Channel
5.1 North America Hospital Pharmacy Market by Country
5.2 North America Retail Pharmacy Market by Country
5.3 North America Online Pharmacy Market by Country
Chapter 6. North America Endometriosis Market by Country
6.1 US Endometriosis Market
6.1.1 US Endometriosis Market by Type
6.1.2 US Endometriosis Market by Treatment
6.1.3 US Endometriosis Market by Distribution Channel
6.2 Canada Endometriosis Market
6.2.1 Canada Endometriosis Market by Type
6.2.2 Canada Endometriosis Market by Treatment
6.2.3 Canada Endometriosis Market by Distribution Channel
6.3 Mexico Endometriosis Market
6.3.1 Mexico Endometriosis Market by Type
6.3.2 Mexico Endometriosis Market by Treatment
6.3.3 Mexico Endometriosis Market by Distribution Channel
6.4 Rest of North America Endometriosis Market
6.4.1 Rest of North America Endometriosis Market by Type
6.4.2 Rest of North America Endometriosis Market by Treatment
6.4.3 Rest of North America Endometriosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Sanofi S.A.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 AbbVie, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Trials and Approvals:
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Trials and Approvals:
7.8 Merck & Co., Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Trials and Approvals:
7.9 GlaxoSmithKline PLC
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Trials and Approvals:
7.9.5.2 Acquisition and Mergers:
7.10. Consilient Health Limited
7.10.1 Company Overview
Companies Mentioned
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sanofi S.A.
- AbbVie, Inc.
- AstraZeneca PLC
- Pfizer, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Methodology
LOADING...
